Literature DB >> 9435220

Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin.

S Sheng1, B Truong, D Fredrickson, R Wu, A B Pardee, R Sager.   

Abstract

The maspin protein has tumor suppressor activity in breast and prostate cancers. It inhibits cell motility and invasion in vitro and tumor growth and metastasis in nude mice. Maspin is structurally a member of the serpin (serine protease inhibitors) superfamily but deviates somewhat from classical serpins. We find that single-chain tissue plasminogen activator (sctPA) specifically interacts with the maspin reactive site loop peptide and forms a stable complex with recombinant maspin [rMaspin(i)]. Major effects of rMaspin(i) are observed on plasminogen activation by sctPA. First, rMaspin(i) activates free sctPA. Second, it inhibits sctPA preactivated by poly-D-lysine. Third, rMaspin(i) exerts a biphasic effect on the activity of sctPA preactivated by fibrinogen/gelatin, acting as a competitive inhibitor at low concentrations (< 0.5 microM) and as a stimulator at higher concentrations. Fourth, 38-kDa C-terminal truncated rMaspin(i) further stimulates fibrinogen/gelatin-associated sctPA. rMaspin(i) acts specifically; it does not inhibit urokinase-type plasminogen activator, plasmin, chymotrypsin, trypsin, or elastase. Our kinetic data are quantitatively consistent with a model in which two segregated domains of maspin interact with the catalytic and activating domains of sctPA. These complex interactions between maspin and sctPA in vitro suggest a mechanism by which maspin regulates plasminogen activation by sctPA bound to the epithelial cell surface.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9435220      PMCID: PMC18448          DOI: 10.1073/pnas.95.2.499

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Mechanism of activation and effect of plasmin in blood.

Authors:  S MULLERTZ
Journal:  Acta Physiol Scand Suppl       Date:  1956

2.  Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937.

Authors:  E K Kruithof; J D Vassalli; W D Schleuning; R J Mattaliano; F Bachmann
Journal:  J Biol Chem       Date:  1986-08-25       Impact factor: 5.157

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates.

Authors:  B Astedt; B Bladh; U Christensen; I Lecander
Journal:  Scand J Clin Lab Invest       Date:  1985-09       Impact factor: 1.713

5.  Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types.

Authors:  V Band; R Sager
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

6.  Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli.

Authors:  D Pennica; W E Holmes; W J Kohr; R N Harkins; G A Vehar; C A Ward; W F Bennett; E Yelverton; P H Seeburg; H L Heyneker; D V Goeddel; D Collen
Journal:  Nature       Date:  1983-01-20       Impact factor: 49.962

7.  Solution structure of the fibrin binding finger domain of tissue-type plasminogen activator determined by 1H nuclear magnetic resonance.

Authors:  A K Downing; P C Driscoll; T S Harvey; T J Dudgeon; B O Smith; M Baron; I D Campbell
Journal:  J Mol Biol       Date:  1992-06-05       Impact factor: 5.469

8.  Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor.

Authors:  I Björk; K Nordling; I Larsson; S T Olson
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

9.  Tumor progression in four mammary epithelial cell lines derived from the same patient.

Authors:  V Band; D Zajchowski; K Swisshelm; D Trask; V Kulesa; C Cohen; J Connolly; R Sager
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

10.  In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.

Authors:  L Ossowski; G Clunie; M T Masucci; F Blasi
Journal:  J Cell Biol       Date:  1991-11       Impact factor: 10.539

View more
  21 in total

Review 1.  The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin.

Authors:  Margarida M Bernardo; Sijana H Dzinic; Maria J Matta; Ivory Dean; Lina Saker; Shijie Sheng
Journal:  J Cell Biochem       Date:  2017-03-21       Impact factor: 4.429

2.  Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation.

Authors:  M Margarida Bernardo; Yonghong Meng; Jaron Lockett; Gregory Dyson; Alan Dombkowski; Alexander Kaplun; Xiaohua Li; Shuping Yin; Sijana Dzinic; Mary Olive; Ivory Dean; David Krass; Kamiar Moin; R Daniel Bonfil; Michael Cher; Wael Sakr; Shijie Sheng
Journal:  Genes Cancer       Date:  2011-11

3.  Prognostic value of nuclear maspin expression for adjuvant 5-fluorouracil-based chemotherapy in advanced gastric cancer.

Authors:  Ke-Feng Lei; Bing-Ya Liu; Xiao-Long Jin; Yan Guo; Min Ye; Zheng-Gang Zhu
Journal:  Exp Ther Med       Date:  2012-03-30       Impact factor: 2.447

4.  G-helix of maspin mediates effects on cell migration and adhesion.

Authors:  Lorna Ravenhill; Laura Wagstaff; Dylan R Edwards; Vincent Ellis; Rosemary Bass
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

5.  Maspin expression in carcinoma ex pleomorphic adenoma.

Authors:  M T Martins; A Altemani; L Freitas; V C Araújo
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

6.  Expression of maspin is associated with the intestinal type of gastric adenocarcinoma.

Authors:  Seong Man Kim; Seong Jin Cho; Woo Young Jang; Duck Hwan Kim; Hyung Sik Shin; Myoung Kuk Jang; Hak Yang Kim; Eun Sook Nam
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

7.  Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells.

Authors:  Yuji Akiyama; Chihaya Maesawa; Satoshi Ogasawara; Masanori Terashima; Tomoyuki Masuda
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

8.  Binding of extracellular maspin to beta1 integrins inhibits vascular smooth muscle cell migration.

Authors:  Rosemary Bass; Laura Wagstaff; Lorna Ravenhill; Vincent Ellis
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

9.  Pathobiological significance of vascular endothelial growth factor and Maspin expressions in human gastric carcinoma.

Authors:  Jian-Jun Li; Ying Chen; Su-Min Zhang; Dong-Ying Wu; Yan-Ping Wang; Yan Xin
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

10.  Discrepancy between mRNA and protein expression of tumour suppressor maspin in synovial tissue may contribute to synovial hyperplasia in rheumatoid arthritis.

Authors:  J Schedel; O Distler; M Woenckhaus; R E Gay; B Simmen; B A Michel; U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.